Reocclusion after thrombolysis: a problem solved by hirudin?

Blood Coagul Fibrinolysis. 1991 Feb;2(1):97-100.

Abstract

The effect of recombinant hirudin (r-hir), unfractionated heparin (UFH) and acetylsalicylic acid (ASA) on the incidence of reocclusion after thrombolysis with plasminogen activator (rt-PA) was evaluated in anaesthetized rabbits. Formation of a platelet rich thrombus was achieved by implantation of a copper coil into the iliac artery. The occluded artery was recanalized in six of ten animals by intravenous administration of rt-PA given as a bolus injection of 0.1 mg/kg followed by infusion of 0.5 mg/kg/h. Within 1 h after termination of rt-PA infusion rethrombosis was observed in 100% of recanalized vessels. The incidence of reocclusion was diminished by r-hir in a dose-dependent manner to 50% after infusion of 0.05 mg/kg/h and to 25% after 0.1 mg/kg/h. No effect on APTT was detectable in this dosage after 3 h infusion. UFH in a dosage increasing APTT two-fold (35 U/kg/h) did not reduce the reocclusion rate. 100 U/kg/h UFH increased APTT to greater than 3 min and reduced reocclusion rates to 50%. ASA showed a minor effect on the incidence of restenosis whereas the combination of 0.1 mg/kg/h r-hir plus bolus injection of 10 mg/kg ASA led to a further reduction in reocclusion rates to only 11% and an increase in reperfusion rates from 60 to 90%. Our experiments indicate that the combination of plasminogen activator with r-hir may be a useful approach for the prophylaxis of early reocclusion.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Aspirin / pharmacology
  • Aspirin / therapeutic use
  • Dose-Response Relationship, Drug
  • Fibrinolytic Agents / pharmacology
  • Fibrinolytic Agents / therapeutic use*
  • Heparin / pharmacology
  • Heparin / therapeutic use
  • Hirudin Therapy
  • Hirudins / analogs & derivatives*
  • Hirudins / pharmacology
  • Iliac Artery
  • Partial Thromboplastin Time
  • Rabbits
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / therapeutic use
  • Recurrence
  • Reperfusion
  • Thrombolytic Therapy*
  • Thrombosis / drug therapy
  • Thrombosis / prevention & control*
  • Tissue Plasminogen Activator / therapeutic use*

Substances

  • Fibrinolytic Agents
  • Hirudins
  • Recombinant Proteins
  • LU 52369
  • Heparin
  • Tissue Plasminogen Activator
  • Aspirin